IDH1 and central nervous system cancer: IDH1/2 mutant gliomas were re-classified according to the 2021 WHO guidelines into oligodendroglioma (ODG, IDH1/2 mutant and 1p/19q co-deleted) and diffuse astrocytoma (DA, IDH1/2 mutant without 1p/19q co-deletion).